Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

496

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: BI 207127-placebo: 8-week treatment
DRUG: Ribavirin: 24-week treatment
DRUG: BI 207127: 24-week treatment
DRUG: Faldaprevir: 24-week treatment
DRUG: Faldaprevir: 24-week treatment
DRUG: Ribavirin-placebo: 8-week treatment
DRUG: BI 207127: 24-week treatment
DRUG: Faldaprevir-placebo: 8-week treatment
DRUG: Faldaprevir: 16-week treatment
DRUG: Ribavirin: 16-week treatment
DRUG: RBV: 24-week treatment
DRUG: BI 207127: 16-week treatment

Sponsor

Boehringer Ingelheim